Success Metrics

Clinical Success Rate
100.0%

Based on 10 completed trials

Completion Rate
100%(10/10)
Active Trials
1(7%)
Results Posted
60%(6 trials)

Phase Distribution

Ph phase_3
4
27%
Ph phase_1
1
7%
Ph phase_2
3
20%
Ph phase_4
5
33%

Phase Distribution

1

Early Stage

3

Mid Stage

9

Late Stage

Phase Distribution13 total trials
Phase 1Safety & dosage
1(7.7%)
Phase 2Efficacy & side effects
3(23.1%)
Phase 3Large-scale testing
4(30.8%)
Phase 4Post-market surveillance
5(38.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

76.9%

10 of 13 finished

Non-Completion Rate

23.1%

3 ended early

Currently Active

1

trials recruiting

Total Trials

15

all time

Status Distribution
Active(1)
Completed(10)
Terminated(3)
Other(1)

Detailed Status

Completed10
Withdrawn3
Recruiting1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
15
Active
1
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (7.7%)
Phase 23 (23.1%)
Phase 34 (30.8%)
Phase 45 (38.5%)

Trials by Status

recruiting17%
unknown17%
completed1067%
withdrawn320%

Recent Activity

Clinical Trials (15)

Showing 15 of 15 trials
NCT07128628Phase 2

A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease

Recruiting
NCT07040826Phase 1

Lifitegrast Eye Drops in Healthy Subjects:Phase I Study

Completed
NCT05857748

Examining the Clinical Characteristics, Treatment Patterns, Real-world Effectiveness, and Healthcare Resource Utilization of Patients With Dry Eye Disease

Withdrawn
NCT04172961Phase 4

Clinical Efficacy of Two Topical Dry Eye Drops for Central Corneal Stain Clearing Over 90 Days

Unknown
NCT00926185Phase 2

A Study Evaluating the Efficacy of SAR 1118 (0.1%, 1.0%, 5.0%) Ophthalmic Solution in Subjects With Dry Eye Conducted in a Controlled Adverse Environment (CAE)

Completed
NCT01743729Phase 3

A Phase 3 Study to Evaluate the Efficacy of Lifitegrast in Subjects With Dry Eye

Completed
NCT00882687Phase 2

Efficacy Study to Evaluate the Effectiveness of 3 Concentrations of SAR 1118 in Allergic Conjunctivitis

Completed
NCT01421498Phase 3

Safety and Efficacy Study of SAR 1118 to Treat Dry Eye Conducted in a Controlled Adverse Environment (CAE) (OPUS-1)

Completed
NCT02284516Phase 3

A Study to Evaluate Efficacy and Safety of Lifitegrast in Subjects With Dry Eye (OPUS-3)

Completed
NCT01636206Phase 3

Safety Study of Lifitegrast to Treat Dry Eye

Completed
NCT03866629

The Effect Of Lifitegrast On Refractive Accuracy And Symptoms In Dry Eye Patients Undergoing Cataract Surgery

Completed
NCT03408015Phase 4

Effects of Xiidra on Closed Eye Tear Film Leukocytes in Dry Eye Disease

Withdrawn
NCT03431272Phase 4

Use of 5.0% Lifitegrast Ophthalmic Solution for the Treatment of Dry Eye Disease in Contact Lens Wearers

Withdrawn
NCT03686878Phase 4

Lifitegrast 5% Ophthalmic Solution and Contact Lens Dryness

Completed
NCT03451396Phase 4

Effect of Lifitegrast on Dry Eye Disease Signs and Symptoms

Completed

All 15 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
15